[March 20, 2013]

Research and Markets: Global Anticoagulants Market to Spike to Over $24 Billion by 2019

Research and Markets (http://www.researchandmarkets.com/research/p9tfcs/new_oral) has announced the addition of the "New Oral Anticoagulants Markets" report to their offering.

Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $1.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.

The "New Oral Anticoagulants Markets" report covers:

- Dabigatran (Pradaxa)

- Rivaroxaban (Xarelto)

- Eliquis (Apixaban)

- Edoxaban

- Betrixaban

- Antiplatelets

- Clotting Assays

- Cardiovascular Diseases

- Cardiac Arrhythmia

- Coronary Artery Disease

- Myocardial Infarction

- Heart Valve Replacement

- Deep Vein Thrombosis (DVT)

The "New Oral Anticoagulants Markets" report examines companies manufacturing anticoagulant equipment and supplies in the world. Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi.

Detailed charts with sales forecasts and marketshare data are included.

For more information visit http://www.researchandmarkets.com/research/p9tfcs/new_oral

[ Back To Technology News's Homepage ]